Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients

Manderbacka, Kristiina; Keskimäki, Ilmo; Reunanen, Antti; Klaukka, Timo

doi:10.1186/1475-9276-7-16

International Journal for Equity in Health

Table 2 Use of antithrombotic drugs, statins and beta-blockers among Finnish CHD-patients in 2001.

From: Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients

MEN		All three			Antithrombotic drugs			Beta-blockers			Statins
		OR	95% CI	p value	OR	95% CI	p =	OR	95% CI	p value	OR	95% CI	p value
Age	45–54	1.00			1.00			1.00			1.00
	55–64	0.80	0.58 – 1.11		0.83	0.40 – 1.72		0.71	0.45 – 1.13		0.87	0.62 – 1.23
	65–74	0.57	0.41 – 0.79	<0.001	0.59	0.30 – 1.18	ns	0.59	0.37 – 0.93	ns	0.57	0.41 – 0.80	<0.001
Income	highest	1.00			1.00			1.00			1.00
third	intermed	0.77	0.58 – 1.01		1.16	0.65 – 2.06		1.05	0.74 – 1.50		0.68	0.51 – 0.90
	lowest	0.81	0.60 – 1.08	ns	0.73	0.42 – 1.29	ns	1.00	0.68 – 1.45	ns	0.64	0.47 – 0.87	<0.01
AMI	no	1.00			1.00			1.00			1.00
	yes	1.34	1.08 – 1.67	<0.01	1.89	1.17 – 3.04	<0.01	1.45	1.09 – 1.95	<0.05	1.26	1.01 – 1.58	<0.05
Use of	less	1.00			1.00			1.00			1.00
nitrates	≥ 1/week	1.09	0.80 – 1.48	ns	0.91	0.50 – 1.64	ns	1.05	0.70 – 1.57	ns	1.00	0.73 – 1.38	ns
Chest pain	no	1.00			1.00			1.00			1.00
	yes	1.00	0.80 – 1.25	ns	0.85	0.54 – 1.33	ns	1.35	1.01 – 1.80	<0.05	0.88	0.70 – 1.11	ns
Diabetes	no	1.00			1.00			1.00			1.00
	yes	0.95	0.69 – 1.29	ns	1.48	0.74 – 2.94	ns	1.56	1.00 – 2.44	ns	0.83	0.61 – 1.14	ns
Heart	no	1.00			1.00			1.00			1.00
failure	yes	0.89	0.69 – 1.16	ns	0.85	0.52 – 1.39	ns	0.97	0.69 – 1.36	ns	0.81	0.62 – 1.06	ns
Revasc.	no	1.00			1.00			1.00			1.00
	yes	2.26	1.81 – 2.82	<0.0001	2.57	1.60 – 4.13	0.0001	1.27	0.96 – 1.68	ns	2.48	1.97 – 3.13	<0.0001
WOMEN		All three			Antithrombotic drugs			Beta-blockers			Statins
		OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value
Age	45–54	1.00			1.00			1.00			1.00
	55–64	1.07	0.68 – 1.67		1.17	0.61 – 2.23		1.18	0.69 – 2.02		1.11	0.71 – 1.74
	65–74	1.31	0.86 – 2.01	ns	1.58	0.85 – 2.95	ns	1.31	0.78 – 2.18	ns	1.46	0.95 – 2.23	<0.01
Income	highest	1.00			1.00			1.00			1.00
third	intermed	1.14	0.83 – 1.55		0.94	0.58 – 1.54		1.06	0.72 – 1.57		1.29	0.94 – 1.77
	lowest	1.05	0.78 – 1.42	ns	0.95	0.59 – 1.54	ns	1.01	0.70 – 1.47	ns	1.18	0.88 – 1.60	ns
AMI	no	1.00			1.00			1.00			1.00
	yes	1.51	1.16 – 1.97	<0.01	2.79	1.60 – 4.89	<0.001	1.51	1.06 – 2.15	<0.05	1.52	1.16 – 2.00	<0.01
Use of	less	1.00			1.00			1.00			1.00
nitrates	≥ 1/week	1.21	0.92 – 1.59	ns	1.11	0.71 – 1.76	ns	0.90	0.64 – 1.27	ns	1.20	0.91 – 1.59	ns
Chest pain	no	1.00			1.00			1.00			1.00
	yes	1.19	0.93 – 1.51	ns	1.14	0.78 – 1.67	ns	1.25	0.93 – 1.68	ns	1.13	0.89 – 1.44	ns
Diabetes	no	1.00			1.00			1.00			1.00
	yes	1.27	0.93 – 1.75	ns	1.26	0.73 – 2.19	ns	1.03	0.69 – 1.54	ns	1.23	0.89 – 1.71	ns
Heart	no	1.00			1.00			1.00			1.00
failure	yes	0.94	0.72 – 1.23	ns	0.96	0.62 – 1.48	ns	1.03	0.73 – 1.45	ns	0.92	0.70 – 1.20	ns
Revasc.	no	1.00			1.00			1.00			1.00
	yes	3.92	2.99 – 5.15	<0.0001	5.55	2.84 – 10.8	<0.0001	2.16	1.50 – 3.11	<0.0001	3.96	2.95 – 5.33	<0.0001

Models for use of each drug controlling only for age, five-year age bands. Odds ratios (OR) and their 95% confidence intervals (CI)

Back to article page

ISSN: 1475-9276

Contact us

General enquiries: journalsubmissions@springernature.com